RP11-874 J12.4 promotes erlotinib resistance in non-small cell lung cancer via increasing AXL expression
- 17 June 2024
- journal article
- research article
- Published by Elsevier in Life Sciences
- Vol. 351, 122849
Abstract
No abstract availableKeywords
Funding Information
- Guangzhou Municipal Science and Technology Program key projects
- National Natural Science Foundation of China
This publication has 35 references indexed in Scilit:
- LncRNA regulation: New frontiers in epigenetic solutions to drug chemoresistanceBiochemical Pharmacology, 2021
- LncRNAs in cancer: Regulatory and therapeutic implicationsCancer Letters, 2021
- EMT: A mechanism for escape from EGFR-targeted therapy in lung cancerBiochimica et Biophysica Acta (BBA) - Reviews on Cancer, 2019
- RETRACTED ARTICLE: LncRNA HOTAIR regulates HIF-1α/AXL signaling through inhibition of miR-217 in renal cell carcinomaCell Death & Disease, 2017
- Lung Cancer Statistics2015
- The TAM family: phosphatidylserine-sensing receptor tyrosine kinases gone awry in cancerNature Reviews Cancer, 2014
- Function of lncRNAs and approaches to lncRNA-protein interactionsScience China Life Sciences, 2013
- Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancerNature Genetics, 2012
- Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 studyThe Lancet Oncology, 2011
- Long non-coding RNA HOTAIR reprograms chromatin state to promote cancer metastasisNature, 2010